Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Autoimmune disease

Pemphigus vulgaris (PV)

Desmoglein 1 (DSG1); DSG3

In vitro and mouse studies identified a DSG-binding peptide that could help treat PV. In a mouse model of a skin disease caused by autoantibodies against DSG1 and DSG3, injection or topical administration of a tandem peptide that bound DSG decreased blistering compared with no peptide treatment. In skin lesions from the mouse model, the DSG-binding peptide prevented autoantibody-induced p38 mitogen-activated protein kinase (p38 MAPK; MAPK14) activation and resulting blistering. Next steps could include optimizing the peptide for topical delivery.

SciBX 6(4); doi:10.1038/scibx.2013.81
Published online Jan. 31, 2013

Patent and licensing status unavailable

Spindler, V. et al. J. Clin. Invest.; published online Jan. 9, 2013;
doi:10.1172/JCI60139
Contact: Jens Waschke, Ludwig Maximilian University of Munich, Munich, Germany
e-mail:
jens.waschke@med.uni-muenchen.de